Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. Signal., 21 July 2009
Vol. 2, Issue 80, p. ra36
[DOI: 10.1126/scisignal.2000308]


Inhibition of mTOR Signaling in Parkinson’s Disease Prevents L-DOPA–Induced Dyskinesia

Emanuela Santini1, Myriam Heiman2, Paul Greengard2, Emmanuel Valjent1,3,4,5, and Gilberto Fisone1,2*

1 Department of Neuroscience, Karolinska Institutet, Retzius väg 8, 171 77 Stockholm, Sweden.
2 Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY 10021, USA.
3 INSERM, UMR-S839, 75005 Paris, France.
4 Université Pierre et Marie Curie, 75005 Paris, France.
5 Institut du Fer à Moulin, 75005 Paris, France.

Abstract: Parkinson’s disease (PD), a disorder caused by degeneration of the dopaminergic input to the basal ganglia, is commonly treated with L-DOPA. Use of this drug, however, is severely limited by motor side effects, or dyskinesia. We show that administration of L-DOPA in a mouse model of Parkinsonism led to dopamine D1 receptor–mediated activation of the mammalian target of rapamycin (mTOR) complex 1 (mTORC1), which is implicated in several forms of synaptic plasticity. This response occurred selectively in the GABAergic medium spiny neurons that project directly from the striatum to the output structures of the basal ganglia. The L-DOPA–mediated activation of mTORC1 persisted in mice that developed dyskinesia. Moreover, the mTORC1 inhibitor rapamycin prevented the development of dyskinesia without affecting the therapeutic efficacy of L-DOPA. Thus, the mTORC1 signaling cascade represents a promising target for the design of anti-Parkinsonian therapies.

* To whom correspondence should be addressed. E-mail: gilberto.fisone{at}

Citation: E. Santini, M. Heiman, P. Greengard, E. Valjent, G. Fisone, Inhibition of mTOR Signaling in Parkinson’s Disease Prevents L-DOPA–Induced Dyskinesia. Sci. Signal. 2, ra36 (2009).

Read the Full Text

Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia.
M. Heiman, A. Heilbut, V. Francardo, R. Kulicke, R. J. Fenster, E. D. Kolaczyk, J. P. Mesirov, D. J. Surmeier, M. A. Cenci, and P. Greengard (2014)
PNAS 111, 4578-4583
   Abstract »    Full Text »    PDF »
Rhes, a Striatal-selective Protein Implicated in Huntington Disease, Binds Beclin-1 and Activates Autophagy.
R. G. Mealer, A. J. Murray, N. Shahani, S. Subramaniam, and S. H. Snyder (2014)
J. Biol. Chem. 289, 3547-3554
   Abstract »    Full Text »    PDF »
The Pharmacology of L-DOPA-Induced Dyskinesia in Parkinson's Disease.
P. Huot, T. H. Johnston, J. B. Koprich, S. H. Fox, and J. M. Brotchie (2013)
Pharmacol. Rev. 65, 171-222
   Abstract »    Full Text »    PDF »
5-HT6 receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia.
J. Meffre, S. Chaumont-Dubel, C. Mannoury la Cour, F. Loiseau, D. J. G. Watson, A. Dekeyne, M. Seveno, J.-M. Rivet, F. Gaven, P. Deleris, et al. (2012)
EMBO Mol Med. 4, 1043-1056
   Abstract »    Full Text »    PDF »
Consolidation and translation regulation.
S. Gal-Ben-Ari, J. W. Kenney, H. Ounalla-Saad, E. Taha, O. David, D. Levitan, I. Gildish, D. Panja, B. Pai, K. Wibrand, et al. (2012)
Learn. Mem. 19, 410-422
   Abstract »    Full Text »    PDF »
Dopamine- and cAMP-regulated Phosphoprotein of 32-kDa (DARPP-32)-dependent Activation of Extracellular Signal-regulated Kinase (ERK) and Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling in Experimental Parkinsonism.
E. Santini, M. Feyder, G. Gangarossa, H. S. Bateup, P. Greengard, and G. Fisone (2012)
J. Biol. Chem. 287, 27806-27812
   Abstract »    Full Text »    PDF »
G{alpha}olf Mutation Allows Parsing the Role of cAMP-Dependent and Extracellular Signal-Regulated Kinase-Dependent Signaling in L-3,4-Dihydroxyphenylalanine-Induced Dyskinesia.
C. Alcacer, E. Santini, E. Valjent, F. Gaven, J.-A. Girault, and D. Herve (2012)
J. Neurosci. 32, 5900-5910
   Abstract »    Full Text »    PDF »
Tonic Dopamine Induces Persistent Changes in the Transient Potassium Current through Translational Regulation.
E. W. Rodgers, W.-D. C. Krenz, and D. J. Baro (2011)
J. Neurosci. 31, 13046-13056
   Abstract »    Full Text »    PDF »
The Physiology, Signaling, and Pharmacology of Dopamine Receptors.
J.-M. Beaulieu and R. R. Gainetdinov (2011)
Pharmacol. Rev. 63, 182-217
   Abstract »    Full Text »    PDF »
Role of Aberrant Striatal Dopamine D1 Receptor/cAMP/Protein Kinase A/DARPP32 Signaling in the Paradoxical Calming Effect of Amphetamine.
F. Napolitano, A. Bonito-Oliva, M. Federici, M. Carta, F. Errico, S. Magara, G. Martella, R. Nistico, D. Centonze, A. Pisani, et al. (2010)
J. Neurosci. 30, 11043-11056
   Abstract »    Full Text »    PDF »
Roles of Fragile X Mental Retardation Protein in Dopaminergic Stimulation-induced Synapse-associated Protein Synthesis and Subsequent {alpha}-Amino-3-hydroxyl-5-methyl-4-isoxazole-4-propionate (AMPA) Receptor Internalization.
H. Wang, S. S. Kim, and M. Zhuo (2010)
J. Biol. Chem. 285, 21888-21901
   Abstract »    Full Text »    PDF »
Science Signaling Podcast: 21 July 2009.
W. Wong and A. M. VanHook (2009)
Science Signaling 2, pc13
   Abstract »    Full Text »
Thwarting Dyskinesia by Targeting mTORC1.
E. Klann (2009)
Science Signaling 2, pe42
   Abstract »    Full Text »    PDF »

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882